Fig. 4

MEKi/HSP90i treatment of LGSOC scaffold model. Treatment group is indicated by color code for the entire figure. A Images of treated LGSOC scaffold model at day 50; phase-contrast, scanning electron microscopy (SEM) and Hematoxylin & Eosin (H&E). Scale bars 100 µm. B Relative cancer cell viability within the treated LGSOC scaffold model determined by BLI. C Total (cancer cells and CAF) glucose consumption (D) and lactate production (E) and lactate/ glucose ratio (F) of control- and combination-treated LGSOC scaffolds from day 47 till 50. G Correlation between treated LGSOC scaffolds and mouse model, based on the AUC of the growth curves. *p < 0.05, **p < 0.01 and ***p < 0.001